Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases
Clinical heterogeneity, a hallmark of systemic autoimmune diseases, impedes early diagnosis and effective treatment, issues that may be addressed if patients could be classified into groups defined by molecular pattern. This study was undertaken to identify molecular clusters for reclassifying systemic autoimmune diseases independently of clinical diagnosis.
Unsupervised clustering of integrated whole blood transcriptome and methylome cross-sectional data on 955 patients with 7 systemic autoimmune diseases and 267 healthy controls was undertaken. In addition, an inception cohort was prospectively followed up for 6 or 14 months to validate the results and analyze whether or not cluster assignment changed over time.
Four clusters were identified and validated. Three were pathologic, representing “inflammatory,” “lymphoid,” and “interferon” patterns. Each included all diagnoses and was defined by genetic, clinical, serologic, and cellular features. A fourth cluster with no specific molecular pattern was associated with low disease activity and included healthy controls. A longitudinal and independent inception cohort showed a relapse–remission pattern, where patients remained in their pathologic cluster, moving only to the healthy one, thus showing that the molecular clusters remained stable over time and that single pathogenic molecular signatures characterized each individual patient.
Patients with systemic autoimmune diseases can be jointly stratified into 3 stable disease clusters with specific molecular patterns differentiating different molecular disease mechanisms. These results have important implications for future clinical trials and the study of nonresponse to therapy, marking a paradigm shift in our view of systemic autoimmune diseases.
|art41610-sup-0001-Material.docxWord document, 12.1 MB||Supplementary Material|
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
- 1, , , , , , et al. Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients [review]. Autoimmun Rev 2013; 12: 537–41.
- 2, . Comparison between 3 diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989; 16: 328–34.
- 3, , , , . Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148–59.
- 4, , , . Preliminary diagnostic criteria for Sjogren's syndrome. Scand J Rheumatol Suppl 1986; 61: 22–5.
- 5, , , , , , et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–11.
- 6, , , , , , et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat Med 2015; 21: 1018–27.
- 7, , , , , , et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610–5.
- 8, , , , , , et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711–23.
- 9, , . Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70: 1068–76.
- 10, , . Anti-citrullinated protein antibody positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and the shared epitope rather than smoking per se. PLoS One 2017; 12:e0180655.
- 11, , , , , , et al. MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun 2014; 15: 210–7.
- 12, , , , , . Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression. Arthritis Rheumatol 2018; 70: 2025–35.
- 13, , , , , , et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016; 165: 551–65.
- 14, , , , , , et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann Rheum Dis 2019; 78: 761–72.
- 15, , , , , , et al. Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjogrens syndrome. Eur J Immunol 2020; 50: 119–29.
- 16, , , , , , et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods 2014; 11: 333–7.
- 17, . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9: 559.
- 18, , , , , , et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008; 29: 150–64.
- 19, , , , , , et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014; 15: 195–204.
- 20 ELIXIR Luxembourg. URL: https://elixir-luxembourg.org/.
- 21. Mixed connective tissue disease: some statements [editorial]. Clin Rheumatol 1982; 1: 81–3.
- 22, , . Mixed connective tissue disease-enigma variations? Rheumatology (Oxford) 2017; 56: 326–33.
- 23, , , , . Moving towards a molecular taxonomy of autoimmune rheumatic diseases [review]. Nat Rev Rheumatol 2018; 14: 75–93.
- 24, , , , , , et al. Multi-center harmonization of flow cytometers in the context of the European "PRECISESADS" project [review]. Autoimmun Rev 2016; 15: 1038–45.
- 25, . Type I interferon: a new player in TNF signaling. Curr Dir Autoimmun 2010; 11: 94–104.
- 26, , , , , , et al. Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Res Ther 2019; 21: 147.
- 27, . Role of C-reactive protein at sites of inflammation and infection [review]. Front Immunol 2018; 9: 754.
- 28, . Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008; 19: 34–41.
- 29, , , , , , et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 2019; 20: 902–14.
- 30, , , , , , et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004; 113: 1722–33.
- 31, , , , , , et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54: 1961–73.
- 32, , , , , . Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis Rheum 2010; 62: 1602–7.
- 33, , , , , , et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016; 75: 1909–16.